2025 NOSCM | Optimal Therapy for Early Stage Triple Negative Breast Cancer

2025 NOSCM | Optimal Therapy for Early Stage Triple Negative Breast Cancer

0% Complete

Course Overview

Dr. Hope Rugo emphasized neoadjuvant therapy for TNBC and the role of pembrolizumab.

Course Content

Course Details

Duration
0.00 hour
Released
Jul 25, 2025
Last Review
Jul 25, 2025
Expires
Jul 25, 2026

Objectives

NA

Target Audience

Physicians
Nurses
Pharmacists
Physician Associates

Faculty & Disclosure

Faculty

Hope S. Rugo, MD, FASCO

Disclosure

<p>NA</p>

Accreditation

NA